Biology-guided radiation tracks tumors in real time using cancer's own signals

A radiation therapy that uses cancer's own biological signals to aim each dose in real time is coming to the southern United States for the first time. Ochsner MD Anderson Cancer Center in New Orleans has installed a biology-guided radiotherapy (BgRT) system at its Baptist campus, making it one of only eight facilities worldwide to offer the treatment.

The approach is currently FDA-approved for patients with primary or metastatic tumors in the lung and bone. Unlike conventional radiation, which targets a fixed area and necessarily irradiates surrounding tissue to account for tumor movement, BgRT tracks the tumor second by second during treatment delivery.

How a tumor becomes its own targeting beacon

The system combines two technologies that have never before been integrated in this way: positron-emission tomography (PET), the gold standard for cancer imaging and staging, and a linear accelerator (LINAC), which delivers the radiation dose.

Just before treatment, the patient receives an injection of a radiopharmaceutical, a tracer molecule that cancer cells preferentially consume. As the cancer metabolizes this tracer, it emits signals that the PET component detects. The system then uses those signals to calculate where and how much radiation to deliver, adjusting the dose in real time as the tumor moves with the patient's breathing or other body motion.

Think of it as a spotlight that follows the performer across the stage, except the performer is a tumor and the spotlight is a precisely calibrated radiation beam. By shifting the dose to track the cancer's actual position, the system reduces the volume of healthy tissue that receives radiation.

Metastatic disease enters the radiation conversation

Troy G. Scroggins Jr., chair of radiation oncology at Ochsner MD Anderson, has pointed to the technology's potential to expand radiotherapy's role beyond early-stage cancers. Conventional radiation struggles with metastatic disease partly because metastases are often small, numerous, and located in tissues that move. BgRT's ability to treat multiple tumors within a single treatment plan while sparing healthy tissue could open a pathway for patients who currently have limited radiation options.

That said, the therapy is still in its early deployment phase. Only eight centers worldwide have the technology, meaning long-term outcome data from large patient populations do not yet exist. The FDA approval covers lung and bone tumors specifically, and whether the approach will prove equally effective for other tumor sites remains to be demonstrated in clinical trials.

Precision versus access

The concentration of BgRT systems in a handful of facilities raises a familiar tension in oncology: the most advanced treatments tend to reach the fewest patients first. Ochsner's installation does extend geographic access for patients in the Gulf South, who previously would have needed to travel to one of seven other centers, several of them outside the United States.

Ochsner Health operates 47 hospitals and more than 370 health and urgent care centers across Louisiana, Mississippi, and the broader Gulf South region, treating more than 40,000 cancer patients annually. The Ochsner Cancer Institute has served patients from all 50 states and 28 countries, with care teams that can include up to 20 multidisciplinary specialists per patient.

What remains to be proven

Several important questions remain open. While the physics of real-time tracking are well established, clinical evidence on whether BgRT meaningfully improves survival, reduces recurrence, or lowers toxicity compared with the best existing radiation techniques is still being gathered. Early-adopter enthusiasm is not a substitute for randomized controlled trial data.

The treatment also requires a radiopharmaceutical injection before each session, adding a step and a cost that standard external beam radiation does not involve. Whether insurance coverage will extend broadly to BgRT, and how cost-effectiveness will compare with existing modalities, are practical questions that will shape the technology's adoption curve.

For patients with lung or bone tumors whose cancers move during treatment, the promise is straightforward: radiation that follows the tumor instead of irradiating a larger field to compensate for motion. How fully that promise translates from engineering to clinical outcomes is the next chapter.